|20.60||+0.1700||+0.83%||Vol 1.74M||1Y Perf -51.63%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||30.47||Analyst Rating||Strong Buy 1.43|
|Potential %||47.91||Finscreener Ranking||★★★★+ 56.33|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.59|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 55.89|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||3.30B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||1.24||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|10 Years||1 077.14%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.54|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.43M|
|Avg. Monthly Volume||2.89M|
|Avg. Quarterly Volume||2.33M|
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 20.6 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 1.75M shares and market capitalization of 3.30B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.
The one-year performance of ACADIA Pharmaceuticals Inc. stock is -51.63%, while year-to-date (YTD) performance is -61.47%. ACAD stock has a five-year performance of -39.04%. Its 52-week range is between 20.12 and 58.72, which gives ACAD stock a 52-week price range ratio of 1.24%
ACADIA Pharmaceuticals Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 5.28, a price-to-sale (PS) ratio of 9.30, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.44%, a ROC of -39.14% and a ROE of -40.57%. The company’s profit margin is -53.82%, its EBITDA margin is -64.20%, and its revenue ttm is $351.69 Million , which makes it $2.20 revenue per share.
Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Strong Buy (1.43), with a target price of $30.47, which is +47.91% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ACADIA Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.09, ATR14 : 3.66, CCI20 : -99.86, Chaikin Money Flow : -0.32, MACD : -5.89, Money Flow Index : 29.20, ROC : -20.83, RSI : 19.69, STOCH (14,3) : 7.45, STOCH RSI : 0.02, UO : 26.21, Williams %R : -92.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $153 825), Austin D. Kim (Sold 12 607 shares of value $590 200 ), Elena Ridloff (Option Excercise at a value of $251 200), Elena Ridloff (Sold 14 117 shares of value $717 029 ), James M. Daly (Option Excercise at a value of $1 385 400), James M. Daly (Sold 52 500 shares of value $2 684 356 ), Michael J. Yang (Option Excercise at a value of $626 770), Michael J. Yang (Sold 31 118 shares of value $1 719 464 ), Srdjan Stankovic (Option Excercise at a value of $7 996 100), Srdjan Stankovic (Sold 365 802 shares of value $18 791 602 ), Stephen R. Davis (Option Excercise at a value of $3 929 999), Stephen R. Davis (Sold 227 409 shares of value $10 568 066 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.